Photo by natallia_jpeg from unsplash
Bispecific drugs (BDs) belong to the family of immunotherapies along with checkpoint inhibitors and CAR‐T cells. In the field of oncology, BDs are designed to simultaneously bind a tumour antigen… Click to show full abstract
Bispecific drugs (BDs) belong to the family of immunotherapies along with checkpoint inhibitors and CAR‐T cells. In the field of oncology, BDs are designed to simultaneously bind a tumour antigen on the one side and an antigen present on the surface of effector cells on the other. This review summarizes the information available to date on the first marketed BiTE‐format bispecific antibody, blinatumomab BLINCYTO® in acute lymphoblastic leukaemia.
Keywords:
pharmacodynamics pharmacokinetics;
pharmacology;
pharmacology blinatumomab;
blinatumomab state;
art pharmacodynamics;
state art
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Journal of Clinical Pharmacy and Therapeutics
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!